Calcium Carbonate
Recommended EndocrinologyAuthority RequiredNot applicable line
Treatment of hyperphosphataemia associated with chronic renal failure.
1
Submissions
2019–19
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Jul 2008 Recommended Chronic renal failure. no PSD
Access path
- Mar 2019Recommended
- PBS listing · Authority Required
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
5.1 The PBAC agreed to the listing of a new pack size of 120 for the currently listed pharmaceutical item calcium, tablet, chewable, 500 mg (as carbonate).PSD · Mar 2019
5.2 The PBAC noted that the sponsor intends to delist the currently listed Cal-500 pack size of 60 tablets once the 120 tablet pack size is listed. Outcome: RecommendedPSD · Mar 2019
Cost-effectiveness
Not modelled — minor submission (pack size change only).
There is expected to be no financial impact as a result of the listing of the 120 tablet pack size on the PBS. PSD · 2019
Cost-effectiveness accepted
Decision context
PopulationPatients with hyperphosphataemia associated with chronic renal failure.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2019 | Recommended | — | — | Cost-minimisation · Cost-minimisation |